Puma Biotechnology Inc
Follow $PBYI
One email when a member of Congress discloses a trade in it, with the official filing receipt linked.
Free. No account. Unsubscribe in one click.
Follow $PBYI by emailVeridion Score
BETAHIGH CONF · 6 of 6 factors measuredHighest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Why is PBYI moving today?
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also, it is developing Alisertib, a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis, resulting in apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
PBYI overview
Related filings and maps
Congress activity in PBYI
No receipt-qualified Congressional disclosure is present for PBYI in the cached public ledger.
PBYI contract awards, year to date.
Public federal awards linked to this ticker.
PBYI lobbying filings, year to date.
Registered lobbying filings matched to Puma Biotechnology Inc.